{
  "id": 20608010,
  "title": "Chinese biotech competition and the payer squeeze are reshaping European biotech",
  "url": "https://urgent.news/2026/11/18/chinese-biotech-competition-and-the-payer-squeeze-are-reshaping",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T09:00:00.000Z",
  "source": {
    "name": "Labiotech",
    "slug": "labiotech",
    "url": "https://www.labiotech.eu/in-depth/chinese-biotech-competition-european-biotech/"
  },
  "original_language": "en",
  "account": null,
  "summary": "At BIO-Europe last week one preclinical company explained how it was building its drug development program with a focus on fitting prescribing and reimbursement models. This direction, the executive explained, was not selected because these models suited cancer interception, but instead because future partners in top pharma would need to be assured of the business […] The post Chinese biotech…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}